Scientists have found a way to transform hard-to-treat tumors into targets for the immune system. Using two protein ...

A multi-institutional team led by University of Washington scientists have engineered a new vaccine platform combining mRNA ...

Researchers at the University of Missouri School of Medicine have recently found that a certain protein may have a large ...

Breakthrough method turns ‘cold’ tumors into immune targets, raising hope for lasting cancer control - Anadolu Ajansı ...

Kernal has been awarded up to $48M funding to accelerate the development of KR-402, a next-generation in vivo CAR T-cell ...

Novel therapies for certain autoimmune diseases have been developed to end B cell-driven immune attacks on normal tissues.

Tr1X has won an FDA green light for a clinical trial testing TRX319, a cell therapy designed to restore immune balance, for ...

Sana Biotechnology, Inc. is a Strong Buy with promising cell therapies for diabetes & B-cell disorders. Click here to find ...

TRX319 is an allogeneic CAR-Tr1 Treg cell therapy designed to pair targeted B-cell control with active anti-inflammatory signaling and pathogenic T-cell modulation in a CNS-penetrant package $50 ...

A nanoparticle-based vaccine prevented melanoma, pancreatic, and breast cancers in mice, keeping up to 88% tumor-free and ...

The embryo-like model could help scientists test new drugs, create stem cells for transplants and research blood disorders ...

Talha Burki speaks with Fred Ramsdell, Mary Brunkow, and Shimon Sakaguchi about their Nobel-winning discoveries in peripheral ...